Alnylam looks cheaper on two of the three valuation measures in this snapshot, while Biogen has the lower price-to-book ratio. The results are mixed, so no single multiple tells the whole story.
Biogen Inc. (BIIB) and Alnylam Pharmaceuticals Inc. (ALNY) are both in the health care sector, in the Pharmaceuticals, Biotechnology & Life Sciences industry group. Their latest adjusted closing prices were US$248.35 and US$155.94, respectively, on 2026-11-06. Alnylam has the lower P/E and PEG ratios, while Biogen has the lower P/B ratio. Here’s what the figures show—and what they don’t.
Investor takeaway: Alnylam screens cheaper on P/E and PEG, while Biogen screens cheaper on P/B. The results are mixed, so neither stock stands out as the clear value choice based on these multiples alone. These ratios don’t establish whether either stock is undervalued or predict future returns.
Stocks in this list
Live snapshots — open any name for the full quote and Wealth Awesome price forecast.
Biogen Inc
BIIB.US
Health Care
$248.35
$36.71B
1D
+1.81%
1W
-2.08%
Alnylam Pharmaceuticals Inc
ALNY.US
Health Care
$155.94
$20.89B
1D
-0.46%
1W
-5.49%
Alnylam leads on two valuation measures; Biogen leads on one
Alnylam’s P/E is 7.9, compared with Biogen’s 107.5. Its PEG is 0.21, versus 3.38 for Biogen. But Biogen’s P/B is lower at 1.94, compared with Alnylam’s 5.79. The comparison is mixed, and these measures don’t capture every factor that can affect a company’s value.
Bull case
Alnylam looks cheaper on two measures: its P/E is 7.9 and its PEG is 0.21. Its reported ROE TTM is 138.1%. These figures may be worth a closer look, but the snapshot doesn’t explain what’s driving the company’s earnings or returns.
Bear case
Alnylam’s P/B of 5.79 is higher than Biogen’s 1.94, so it doesn’t look cheaper on every measure. Its high reported ROE also needs more context than this snapshot provides. A low P/E or PEG alone doesn’t prove a stock is undervalued.
The valuation snapshot is split
Alnylam has the lower P/E at 7.9, compared with Biogen’s 107.5, and the lower PEG at 0.21, compared with 3.38. On those measures, Alnylam screens cheaper. Biogen has the lower P/B at 1.94, while Alnylam’s is 5.79. The results are mixed, so the three multiples don’t point to a clear winner. P/E, PEG and P/B each show only part of a company’s financial picture, and the snapshot doesn’t explain the differences.
Company figures add context, not a verdict
Biogen’s market cap is US$36.7B, compared with US$20.9B for Alnylam. Their reported ROE TTM figures are 1.9% and 138.1%, respectively. Both have a dividend yield of 0.00%. The snapshot lists a Buy analyst consensus for each, with price targets of US$266.39 for Biogen and US$302.56 for Alnylam. These figures aren’t guarantees of future performance, and they don’t replace understanding how each company earns money. For more company details, see Biogen and Alnylam Pharmaceuticals.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
